Epstein-Barr, Antibodies (IgM) anti-VCA. Screening.

Clinical information

Diagnostic Utility:

This is the qualitative detection of IgM antibodies against the viral capsid antigen (VCA) of the Epstein-Barr virus (EBV), and its determination is useful in:

• Diagnosis of acute EBV infection.
• Diagnosis of infectious mononucleosis (IM).

Method:

Chemiluminescence microparticle immunoassay (CMIA).

Reference Values

Possible results are: Reactive and Non-reactive.

Diagnostic Algorithm:

In case of a reactive result for Epstein-Barr Antibodies (IgM) anti-VCA, the detection test can be requested:

(*) Only performed upon request

Turnaround Time:

Maximum of 5 working days.

Specimen information

Sample: Serum and/or plasma
Tube: Aliquots of 1-5 mL, plasma tubes with EDTA, citrate, or heparin as anticoagulant and/or serum tubes with or without gel separator.
Minimum essential volume: 1 ml
Stability:

• At room temperature: ≤ 3 days
• In refrigeration at 2-8 ºC: ≤14 days
• Sample frozen at or below -20ºC: 10 years

Transport instructions: Preferably at room temperature if they are whole blood tubes and refrigerated if they are serum and/or plasma aliquots.

Reason for rejection: Sample highly hemolyzed.

Administrative information

Code BST: 2109

Description of the test: Epstein-Barr, Antibodies (IgM) anti-VCA. Screening.

Synonyms: EBV VCA IgM

Section: Transfusional Safety Laboratory

BST Rate: Check the updated rates here.

Profiles:

The test 2109 Epstein-Barr, Antibodies (IgM) anti-VCA. Screening can be requested alone or with the following profiles:

References

• Inserts kits de EBV VCA IgM Architect, Abbott.

Quality

BST holds ISO 9001, ISO 14001, and OSHAS 18001 quality certifications, as well as the European Excellence 500+ seal. BST is accredited by CAT, JACIE-FACT, FACT-NETCORD, and EFI, and complies with Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) guidelines.